FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Feldman

Research Profile

Chemicals & Drugs

Procedures

Double-Blind Method

Concepts & Ideas

Disorders

Living Beings

Anatomy

Co-author Network

Publications

TOP 3
Hong Liu-Seifert; Olawale O Osuntokun; Jenna L Godfrey; Peter Feldman
Patient perspectives on antipsychotic treatments and their association with clinical outcomes.
Richard C Mohs; Thomas M Shiovitz; Pierre N. Tariot; Anton P Porsteinsson; Kurt D Baker; Peter Feldman
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Jan K Buitelaar; Timothy E Wilens; Shuyu Zhang; Yu Ning; Peter Feldman
Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Feldman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Hong Liu-Seifert; Olawale O Osuntokun; Jenna L Godfrey; Peter Feldman
Patient perspectives on antipsychotic treatments and their association with clinical outcomes.
Patient preference and adherence 2010;4():369-77.
2009: Richard C Mohs; Thomas M Shiovitz; Pierre N. Tariot; Anton P Porsteinsson; Kurt D Baker; Peter Feldman
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2009;17(9):752-9.
2009: Jan K Buitelaar; Timothy E Wilens; Shuyu Zhang; Yu Ning; Peter Feldman
Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.
Journal of child psychology and psychiatry, and allied disciplines 2009;50(3):335-42.
2008: Paula T Trzepacz; David W Williams; Peter Feldman; Rebecca E Wrishko; Jennifer W Witcher; Jan K Buitelaar
CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2008;18(2):79-86.
2008: Thomas J Spencer; Floyd R Sallee; Donald L Gilbert; David W Dunn; James T McCracken; Barbara J Coffey; Cathy L Budman; Randall K Ricardi; Henrietta L Leonard; Albert J Allen; Denái R Milton; Peter Feldman; Douglas Kelsey; Daniel A Geller; Steven L Linder; Donald W Lewis; Paul Winner; Roger Kurlan; Mark Mintz
Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
Journal of attention disorders 2008;11(4):470-81.
2007: Thomas J Spencer; Christopher J Kratochvil; R Bart Sangal; Keith E Saylor; Charles E Bailey; David W Dunn; Daniel A Geller; Charles D Casat; Robert S Lipetz; Rakesh Jain; Jeffrey H Newcorn; Dustin D Ruff; Peter Feldman; Amanda J Furr; Albert J Allen
Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.
Journal of child and adolescent psychopharmacology 2007;17(5):689-700.
2007: Humberto Quintana; Edward A Cherlin; David A Duesenberg; Mark E Bangs; Janet L Ramsey; Peter Feldman; Albert J Allen; Douglas Kelsey
Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Clinical therapeutics 2007;29(6):1168-77.
2007: Laurence L Greenhill; Jeffrey H Newcorn; Haitao Gao; Peter Feldman
Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine.
Journal of the American Academy of Child and Adolescent Psychiatry 2007;46(5):566-72.
2007: Joseph Biederman; Thomas J Spencer; Jeffrey H Newcorn; Haitao Gao; Denái R Milton; Peter Feldman; Michael M Witte
Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.
Psychopharmacology 2007;190(1):31-41.
2006: Christopher J Kratochvil; Timothy E Wilens; Laurence L Greenhill; Haitao Gao; Kurt D Baker; Peter Feldman; Douglas L Gelowitz
Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder.
Journal of the American Academy of Child and Adolescent Psychiatry 2006;45(8):919-27.
2006: Timothy E Wilens; Jeffrey H Newcorn; Christopher J Kratochvil; Haitao Gao; Christine K Thomason; Ann K Rogers; Peter Feldman; Louise R Levine
Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
The Journal of pediatrics 2006;149(1):112-9.
2005: Albert J Allen; Roger Kurlan; D L Gilbert; Barbara J Coffey; S L Linder; D W Lewis; Paul Winner; David W Dunn; Leon S Dure; Floyd R Sallee; Denái R Milton; M I Mintz; Randall K Ricardi; Gerald Erenberg; L L Layton; Peter Feldman; Douglas Kelsey; Thomas J Spencer
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
Neurology 2005;65(12):1941-9.
2005: Kelvin Lin-Yu Chou; Susan Messing; David Oakes; Peter Feldman; Alan Breier; Joseph H Friedman
Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.
Clinical neuropharmacology 2005;28(5):215-9.
2005: Walter Deberdt; Maurice W Dysken; Stephen A Rappaport; Peter Feldman; Carrie A Young; Donald P Hay; Deborah L Lehman; Martin Dossenbach; Elisabeth K Degenhardt; Alan Breier
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2005;13(8):722-30.
2005: Peter Feldman; Dustin D Ruff; Albert J Allen
Atomoxetine and tics in ADHD.
Journal of the American Academy of Child and Adolescent Psychiatry 2005;44(5):405-6.
2004: Mauricio Tohen; K N Roy Chengappa; Trisha Suppes; Robert W Baker; Carlos A Zarate; Charles L Bowden; Gary S Sachs; David J Kupfer; S Nassir Ghaemi; Peter Feldman; Richard Risser; Angela R Evans; Joseph Calabrese
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone.
The British journal of psychiatry : the journal of mental science 2004;184():337-45.
2004: Peter Paul De Deyn; Manuel Martín Carrasco; Walter Deberdt; Claude Jeandel; Donald P Hay; Peter Feldman; Carrie A Young; Deborah L Lehman; Alan Breier
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.
International journal of geriatric psychiatry 2004;19(2):115-26.
2004: Peter Feldman; Linda K Hay; Walter Deberdt; John S Kennedy; David S Hutchins; Donald P Hay; Thomas A Hardy; Vicki Poole Hoffmann; Kenneth Hornbuckle; Alan Breier
Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
Journal of the American Medical Directors Association 2004;5(1):38-46.
2004: István Bitter; Martin Dossenbach; Shlomo Brook; Peter Feldman; Stephen Metcalfe; Carlo A Gagiano; János Füredi; György Bartko; Zoltan Janka; Csaba M Banki; Gabor Kovacs; Alan Breier
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
Progress in neuro-psychopharmacology & biological psychiatry 2004;28(1):173-80.
2003: Peter Feldman; Christopher J Kaiser; John S Kennedy; Virginia K Sutton; Pierre V Tran; Gary D Tollefson; Fan Zhang; Alan Breier
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
The Journal of clinical psychiatry 2003;64(9):998-1004.
2003: Todd M Sanger; Mauricio Tohen; Eduard Vieta; David L Dunner; Charles L Bowden; Joseph Calabrese; Peter Feldman; Thomas G Jacobs; Alan Breier
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling.
Journal of affective disorders 2003;73(1-2):155-61.
2002: Alan Breier; Virginia K Sutton; Peter Feldman; Deborah L Kadam; Iris Ferchland; Padraig Wright; Joseph H Friedman
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.
Biological psychiatry 2002;52(5):438-45.
2002: Karena Meehan; Huei Wang; Stacy R David; Jennifer R Nisivoccia; Barry Jones; Charles Beasley; Peter Feldman; Jacobo E Mintzer; Louise M Beckett; Alan Breier
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002;26(4):494-504.
2002: Mauricio Tohen; K N Roy Chengappa; Trisha Suppes; Carlos A Zarate; Joseph Calabrese; Charles L Bowden; Gary S Sachs; David J Kupfer; Robert W Baker; Richard Risser; Elisabeth L Keeter; Peter Feldman; Gary D Tollefson; Alan Breier
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.
Archives of general psychiatry 2002;59(1):62-9.
2001: Mauricio Tohen; Fan Zhang; Paul E Keck; Peter Feldman; Richard Risser; Pierre V Tran; Alan Breier
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.
Journal of affective disorders 2001;67(1-3):133-40.
2001: JS Street; WS Clark; Deborah L Kadam; S J Mitan; B E Juliar; Peter Feldman; Alan Breier
Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.
International journal of geriatric psychiatry 2001;16 Suppl 1():S62-70.
2001: J A Frazier; J Biederman; Mauricio Tohen; Peter Feldman; Thomas G Jacobs; V Toma; M A Rater; R A Tarazi; G S Kim; S B Garfield; M Sohma; J Gonzalez-Heydrich; Richard Risser; Z M Nowlin
A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.
Journal of child and adolescent psychopharmacology 2001;11(3):239-50.
2001: WS Clark; JS Street; Peter Feldman; Alan Breier
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
The Journal of clinical psychiatry 2001;62(1):34-40.
2001: Richard C Shelton; Gary D Tollefson; Mauricio Tohen; S Stahl; K S Gannon; Thomas G Jacobs; W R Buras; Frank P Bymaster; W Zhang; K A Spencer; Peter Feldman; Herbert Y Meltzer
A novel augmentation strategy for treating resistant major depression.
The American journal of psychiatry 2001;158(1):131-4.
2000: JS Street; WS Clark; K S Gannon; Jeffrey L Cummings; Frank P Bymaster; Roy Tamura; S J Mitan; Deborah L Kadam; Todd M Sanger; Peter Feldman; Gary D Tollefson; Alan Breier
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
Archives of general psychiatry 2000;57(10):968-76.
2000: Mauricio Tohen; Thomas G Jacobs; Peter Feldman
Onset of action of antipsychotics in the treatment of mania.
Bipolar disorders 2000;2(3 Pt 2):261-8.
1996: Peter Feldman; N Parveen; Sena F Sezen
Cardiovascular effects of Leu-enkephalin in the nucleus tractus solitarius of the rat.
Brain research 1996;709(2):331-36.
1995: Peter Feldman
Effects of serotonin-1 and serotonin-2 receptor agonists on neuronal activity in the nucleus tractus solitarius.
Journal of the autonomic nervous system 1995;56(1-2):119-24.
1995: Peter Feldman; F J Galiano
Cardiovascular effects of serotonin in the nucleus of the solitary tract.
The American journal of physiology 1995;269(1 Pt 2):R48-56.
1995: Peter Feldman
Neurokinin1 receptor mediation of the vasodepressor effects of substance P in the nucleus of the tractus solitarius.
The Journal of pharmacology and experimental therapeutics 1995;273(2):617-23.
1995: Peter Feldman; F J Galiano
Evidence against a hemodynamic role for serotonin in the dorsal motor nucleus of the vagus.
Brain research bulletin 1995;37(5):457-62.
1994: Peter Feldman
Electrophysiological effects of serotonin in the solitary tract nucleus of the rat.
Naunyn-Schmiedeberg's archives of pharmacology 1994;349(5):447-54.
1991: Peter Feldman; Robert B Felder
Effects of gamma-aminobutyric acid and glycine on synaptic excitability of neurones in the solitary tract nucleus.
Neuropharmacology 1991;30(3):225-36.
1989: Peter Feldman; Robert B Felder
Alpha-adrenergic influences on neuronal responses to visceral afferent input in the nucleus tractus solitarius.
Neuropharmacology 1989;28(10):1081-7.
1989: Peter Feldman; Robert B Felder
Alpha 2-adrenergic modulation of synaptic excitability in the rat nucleus tractus solitarius.
Brain research 1989;480(1-2):190-7.
1988: Peter Feldman; Hylan C Moises
Electrophysiological evidence for alpha 1- and alpha 2-adrenoceptors in solitary tract nucleus.
The American journal of physiology 1988;254(4 Pt 2):H756-62.
1987: Peter Feldman; Hylan C Moises
Adrenergic responses of baroreceptive cells in the nucleus tractus solitarii of the rat: a microiontophoretic study.
Brain research 1987;420(2):351-61.
1982: L Wetstein; M B Simson; Peter Feldman; A H Harken
Pharmacologic modification of myocardial ischemia.
Circulation 1982;66(3):548-54.